Clinical anticachexia treatments

Michael J. Tisdale*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Cachexia involves progressive loss of adipose tissue and skeletal muscle mass and is common in a number of end-stage diseases. Cachexia causes weakness and immobility, reduces the quality of life of the patient, and eventually results in death. We reviewed the medical literature concentrating upon agents that have undergone clinical evaluation for the treatment of patients with cachexia. These agents are discussed, together with their mechanisms of action. Megestrol acetate, corticosteroids, eicosapentaenoic acid, and thalidomide have shown some success in the treatment of cachexia. β-hydroxy-β- methylbutyrate, cyclooxygenase inhibitors, adenosine 5′-triphosphate, and growth hormone are undergoing clinical evaluation. Appetite stimulants such as cannabinoids and antiserotonic agents have been shown to be ineffective in preventing progressive weight loss in cachexia. Much of the success in the treatment of cachexia has come from agents capable of blocking protein degradation through the ubiquitin-proteasome proteolytic pathway. Muscle mass can be increased when such agents are combined with agents that stimulate protein synthesis. In order to develop new agents, more fundamental research is required on the cellular mechanisms governing protein synthesis and degradation in skeletal muscle in cachexia.

Original languageEnglish
Pages (from-to)168-174
Number of pages7
JournalNutrition in Clinical Practice
Volume21
Issue number2
DOIs
Publication statusPublished - 1 Apr 2006

Fingerprint

cachexia
Cachexia
protein degradation
Therapeutics
Proteolysis
skeletal muscle
Appetite Stimulants
Skeletal Muscle
protein synthesis
megestrol
Megestrol Acetate
cannabinoids
Thalidomide
Eicosapentaenoic Acid
adenosine triphosphate
Cyclooxygenase Inhibitors
Cannabinoids
proteasome endopeptidase complex
prostaglandin synthase
Proteasome Endopeptidase Complex

Cite this

Tisdale, Michael J. / Clinical anticachexia treatments. In: Nutrition in Clinical Practice. 2006 ; Vol. 21, No. 2. pp. 168-174.
@article{91690df94eb74cde8bc8f152664dbcd8,
title = "Clinical anticachexia treatments",
abstract = "Cachexia involves progressive loss of adipose tissue and skeletal muscle mass and is common in a number of end-stage diseases. Cachexia causes weakness and immobility, reduces the quality of life of the patient, and eventually results in death. We reviewed the medical literature concentrating upon agents that have undergone clinical evaluation for the treatment of patients with cachexia. These agents are discussed, together with their mechanisms of action. Megestrol acetate, corticosteroids, eicosapentaenoic acid, and thalidomide have shown some success in the treatment of cachexia. β-hydroxy-β- methylbutyrate, cyclooxygenase inhibitors, adenosine 5′-triphosphate, and growth hormone are undergoing clinical evaluation. Appetite stimulants such as cannabinoids and antiserotonic agents have been shown to be ineffective in preventing progressive weight loss in cachexia. Much of the success in the treatment of cachexia has come from agents capable of blocking protein degradation through the ubiquitin-proteasome proteolytic pathway. Muscle mass can be increased when such agents are combined with agents that stimulate protein synthesis. In order to develop new agents, more fundamental research is required on the cellular mechanisms governing protein synthesis and degradation in skeletal muscle in cachexia.",
author = "Tisdale, {Michael J.}",
year = "2006",
month = "4",
day = "1",
doi = "10.1177/0115426506021002168",
language = "English",
volume = "21",
pages = "168--174",
journal = "Nutrition in Clinical Practice",
issn = "0884-5336",
publisher = "SAGE",
number = "2",

}

Clinical anticachexia treatments. / Tisdale, Michael J.

In: Nutrition in Clinical Practice, Vol. 21, No. 2, 01.04.2006, p. 168-174.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical anticachexia treatments

AU - Tisdale, Michael J.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Cachexia involves progressive loss of adipose tissue and skeletal muscle mass and is common in a number of end-stage diseases. Cachexia causes weakness and immobility, reduces the quality of life of the patient, and eventually results in death. We reviewed the medical literature concentrating upon agents that have undergone clinical evaluation for the treatment of patients with cachexia. These agents are discussed, together with their mechanisms of action. Megestrol acetate, corticosteroids, eicosapentaenoic acid, and thalidomide have shown some success in the treatment of cachexia. β-hydroxy-β- methylbutyrate, cyclooxygenase inhibitors, adenosine 5′-triphosphate, and growth hormone are undergoing clinical evaluation. Appetite stimulants such as cannabinoids and antiserotonic agents have been shown to be ineffective in preventing progressive weight loss in cachexia. Much of the success in the treatment of cachexia has come from agents capable of blocking protein degradation through the ubiquitin-proteasome proteolytic pathway. Muscle mass can be increased when such agents are combined with agents that stimulate protein synthesis. In order to develop new agents, more fundamental research is required on the cellular mechanisms governing protein synthesis and degradation in skeletal muscle in cachexia.

AB - Cachexia involves progressive loss of adipose tissue and skeletal muscle mass and is common in a number of end-stage diseases. Cachexia causes weakness and immobility, reduces the quality of life of the patient, and eventually results in death. We reviewed the medical literature concentrating upon agents that have undergone clinical evaluation for the treatment of patients with cachexia. These agents are discussed, together with their mechanisms of action. Megestrol acetate, corticosteroids, eicosapentaenoic acid, and thalidomide have shown some success in the treatment of cachexia. β-hydroxy-β- methylbutyrate, cyclooxygenase inhibitors, adenosine 5′-triphosphate, and growth hormone are undergoing clinical evaluation. Appetite stimulants such as cannabinoids and antiserotonic agents have been shown to be ineffective in preventing progressive weight loss in cachexia. Much of the success in the treatment of cachexia has come from agents capable of blocking protein degradation through the ubiquitin-proteasome proteolytic pathway. Muscle mass can be increased when such agents are combined with agents that stimulate protein synthesis. In order to develop new agents, more fundamental research is required on the cellular mechanisms governing protein synthesis and degradation in skeletal muscle in cachexia.

UR - http://www.scopus.com/inward/record.url?scp=33747041711&partnerID=8YFLogxK

U2 - 10.1177/0115426506021002168

DO - 10.1177/0115426506021002168

M3 - Article

C2 - 16556927

AN - SCOPUS:33747041711

VL - 21

SP - 168

EP - 174

JO - Nutrition in Clinical Practice

JF - Nutrition in Clinical Practice

SN - 0884-5336

IS - 2

ER -